Outcomes of surveillance versus adjuvant chemotherapy for patients with stage IA and IB nonseminomatous testicular germ cell tumors

GÜMÜŞ M., Bilici A., Odabas H., Ustaalioglu B. B. O. , Kandemir N., Demirci U., ...More

WORLD JOURNAL OF UROLOGY, vol.35, no.7, pp.1103-1110, 2017 (Journal Indexed in SCI) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 35 Issue: 7
  • Publication Date: 2017
  • Doi Number: 10.1007/s00345-016-1964-6
  • Title of Journal : WORLD JOURNAL OF UROLOGY
  • Page Numbers: pp.1103-1110
  • Keywords: Stage I, Nonseminomatous germ cell tumor, Testicular cancer, Chemotherapy, Surveillance, LYMPH-NODE DISSECTION, TERM-FOLLOW-UP, CISPLATIN CHEMOTHERAPY, TESTIS CANCER, RISK, BLEOMYCIN, ETOPOSIDE, MANAGEMENT, TRIAL


Background Currently, it is accepted that risk assessment of clinical stage I (CS I) nonseminomatous germ cell tumors (NSGCT) patient is mainly dependent on the presence of lymphovascular invasion (LVI). Initial active surveillance, adjuvant chemotherapy and retroperitoneal lymph node dissection (RPLND) are acceptable treatment options for these patients, but there is no uniform consensus. The purpose of this study was to compare outcomes of active surveillance with adjuvant chemotherapy.